The AHA Sept. 9 released a report highlighting how hospitals’ arrangements with community and specialty pharmacies improve access to care for underserved patients.

“The accessibility of community pharmacies presents a convenient, familiar, and dependable source of care,” the report notes. “This is especially true for those living in rural communities or who lack easy access to transportation.”

The report includes a number of data points on how 340B community and specialty pharmacies are located in counties that are experiencing issues that affect individuals’ health, including lack of insurance, food insecurity, high unemployment and severe housing problems.

“Importantly, these arrangements allow hospitals to better fulfill their 340B mission — to stretch scarce resources and expand access to care for more patients,” the report notes. “Collectively these data demonstrate the need for Congress to continue its strong bipartisan support of the program and reject efforts by big drug companies to undermine the program and the innumerable benefits it affords patients across the country.”
 

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…